Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2026 08:00 ET | Source: Replimune, Inc.

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
May 28, 2026 19:02 ET | Source: TermPlus

TermPlus Fixed-Term Accounts Combine High-Yield Monthly Income With a Three-Layer Protection System and Target Rates from 7.35% Per annum for One-Year and Up To 8.50%* Per Annum for Five-Years

Sydney, Australia, May 29, 2026 (GLOBE NEWSWIRE) -- A growing number of Australians are looking for income-generating options that pair competitive returns with a clear, built-in approach to capital...
May 28, 2026 10:13 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Upcoming Conferences in June

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic...
May 28, 2026 09:10 ET | Source: Medicenna Therapeutics Corp.

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)...
May 28, 2026 08:50 ET | Source: Entera Bio Ltd.

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across...
May 28, 2026 08:00 ET | Source: Medicus Pharma Ltd

Medicus Pharma Announces $22 Million Non-Dilutive Financing

PHILADELPHIA, May 28, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs...
May 28, 2026 08:00 ET | Source: Immutep Limited

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

SYDNEY, AUSTRALIA, May 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune...
May 28, 2026 07:00 ET | Source: NovaBridge Biosciences

NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to...
May 28, 2026 04:00 ET | Source: Anaveon

Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 & actively seeks Partners for its Legacy Oncology Portfolio.
May 27, 2026 18:55 ET | Source: TermPlus

Self-Managed Super Fund Trustees and Investors Explore High-Yield Fixed-Term Accounts from TermPlus as Cash Allocations Fall Across Australia’s A$1.06 Trillion SMSF Sector

Sydney, Australia, May 28, 2026 (GLOBE NEWSWIRE) -- For the trustees of Australia’s 663,867 self-managed super funds, the income side of the portfolio has come under closer scrutiny. The latest...